{"id":"bay3018250-dose-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of BAY3018250 is not well understood, but it is believed to work by interacting with the molecular target, leading to a specific therapeutic effect.","oneSentence":"BAY3018250 is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:22:23.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 clinical trials for BAY3018250 are ongoing, but the specific indication is not publicly disclosed."}]},"trialDetails":[{"nctId":"NCT06149520","phase":"PHASE2","title":"A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-01-15","conditions":"Thrombolysis, Symptomatic Proximal Deep Vein Thrombosis","enrollment":258},{"nctId":"NCT06619483","phase":"PHASE1","title":"A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-10-10","conditions":"Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers","enrollment":24},{"nctId":"NCT06562985","phase":"PHASE1","title":"A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-09-18","conditions":"Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BAY3018250 Dose 1","genericName":"BAY3018250 Dose 1","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAY3018250 is a small molecule drug that targets the molecular target. Used for Phase 2 clinical trials for BAY3018250 are ongoing, but the specific indication is not publicly disclosed..","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}